CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 17 enrolled
Drug / intervention
Boceprevir +1 moredrug
Likely dose
Boceprevir 200 mg and St John's Wort 300 mgAI-extracted
Key inclusion· 5
  • Age 18–65 years inclusive
  • BMI 18–35 kg/m² inclusive
  • Males or non-pregnant, non-lactating females
  • Females of childbearing potential must use adequate non-hormonal contraception (diaphragm with spermicide, intrauterine device) plus condoms; avoid hormonal contraceptives with drospirenone
Key exclusion· 10
  • Any significant acute or chronic medical illness
  • Evidence of organ dysfunction or clinically significant abnormality on physical exam, vital signs, ECG, or lab tests
  • Positive hepatitis B and/or C antibody screening
  • Positive HIV-1 and/or HIV-2 antibody screening

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01663922
NCT01663922Phase 1Completed

Phase I Evaluation of the Pharmacokinetics and Safety of Boceprevir and Ucalm (St John&Apos;s Wort) When Co-administered to Male and Female Healthy Volunteers.

St Stephens Aids Trust·interventional·Posted Aug 13, 2012·Updated Sep 29, 2014

In Brief

A Phase 1 clinical trial evaluating Boceprevir and St John's Wort for Hepatitis C. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The purpose of the study is to look at whether taking a new medication for hepatitis C (boceprevir) together with a herbal remedy commonly used for the treatment of depression (SJW) has any effect on the levels of boceprevir in the blood, compared to when boceprevir is taken on its own. Treatment of hepatitis C genotype-1, has recently been significantly improved with the addition of a new class of drugs called protease inhibitors (PIs). Boceprevir belongs to this class of antiviral drugs and it is administered in combinations with other drugs to treat hepatitis C. One of the common side effects of treatment for hepatitis C is low mood (depression) for which treated patients may self-medicate with preparations containing St. Johns Wort (SJW). SJW is known to cause drug interactions, so taking SJW at the same time as boceprevir may result in a change in how both of these drugs usually work. It is therefore important to find out if the levels of boceprevir in the blood are significantly affected by taking SJW. The study aims to help us understand whether it will be safe to take SJW whilst being simultaneously treated for hepatitis C with boceprevir.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
CountriesUnited Kingdom

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 13, 2012
Enrollment StartAug 1, 2012
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.9 years ago

Interventions

Boceprevirdrug

Boceprevir as Victrelis(r) 200mg capsules

St John's Wortdrug

Each Ucalm(r) tablet contains 300mg of St Johns Wort extract